Introducing a Blocking Reagents to Overcome BSA Challenges

Advancing the Diagnosis with a Japanese quality. MBL (Medical & Biological Laboratories Co., Ltd.), Japan’s first antibody producer, has driven diagnostic innovation since 1969. As the IVD market grows, we offer high-quality raw materials latex beads, magnetic beads, blocking reagents & antibodies combining affordability with trusted Japanese quality.

In the development of in vitro diagnostic reagents, techniques such as chemiluminescence and latex turbidimetry frequently rely on bovine serum albumin (BSA) as a blocking reagent or buffer component. Despite being the most used protein excipient, BSA presents several challenges, including inconsistencies in use, significant batch-to-batch variations, and import difficulties. Additionally, in certain clinical samples, particularly those from young children, the elderly, and patients with autoimmune diseases, antibodies can specifically react with BSA, resulting in false positives and other complications.

Leveraging its expertise in polymer synthesis, JSR has developed three types of fully chemically synthesized blocking reagents, each with distinct characteristics and applications, to address scenarios where BSA falls short. Among these, we are pleased to introduce DB1130, a widely used blocking reagents that we believe will inspire new approaches in your blocking reagents selection process. 

DB1130 is designed to counter the aggregation of colloidal particles in solution, a phenomenon largely attributed to the adsorption forces of hydrophobic segments. By incorporating an optimal balance of hydrophilic and hydrophobic groups, DB1130 effectively manipulates these forces. The hydrophobic groups are drawn to the hydrophobic portions of colloidal particles, while the hydrophilic groups enhance overall hydrophilicity. This dual action prevents aggregation and minimizes nonspecific adsorption during immune responses.

DB1130 blocking reagents is primarily designed to serve as a substitute for BSA, aiming to match both its usage levels and functional efficacy. 

DB1130 Closure Effect: On a luminescent platform, we plan to gradually substitute BSA with DB1130 in both the blocking reagents and buffer compositions to assess the effectiveness of DB1130 as a replacement across various usage scenarios.

Calibrators: The calibration curves for the four conditions align exceptionally well.

Clinical Sample: The correlation between Condition 1, which exclusively used BSA, and Conditions 2,3, and 4, which incrementally integrated DB1130, was remarkably strong. These results indicate that DB1130 can effectively replace BSA in both blocking reagents and buffer components.

Furthermore, DB1130 demonstrated superior suppression of negative sample jump values and an enhanced signal-to-noise ratio in certain programs.

In practical applications, numerous R&D experts have reported that DB1130 enhances stability and mitigates false-positive effects. As a protein-free chemical, DB1130 significantly minimizes the variability and unpredictability associated with protein-based agents.

Additionally, DB1130 demonstrated superior suppression of negative sample jump values and improved the signal-to-noise ratio in certain applications.

Hope that every researcher experiences smooth experiments.

We are here to help you!

Explore our Product Catalog by clicking the link below.

IVD Raw materials | Diagnostic Reagents | MBL | MEDICAL & BIOLOGICAL LABORATORIES CO.,LTD.

For further information, please don't hesitate to contact us,

MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8 Shibadaimon, Minato-ku, Tokyo 105-0012 Japan

E-mail: inquiry-ivd＠mbl.co.jp

https://www.mblbio.com/e/